TNF‐α signalling, together with several other immune‐related pathways, including interferon response and complement activation, were highly enriched, overall suggesting that targeting neuroinflammation for therapy is key to achieving a beneficial effect in SMA. The gene discussed is TNF; the disease is proximal spinal muscular atrophy.